GH Stock — Guardant Health Inc.

Guardant Health Inc. (GH)

Updated October 16, 2026.

GH is a Stock. Total return is 392.5% over the past 8 years, 195.3 points ahead of SPY at 197.2%.

Guardant Health is a precision oncology company that develops and provides blood and tissue tests for cancer detection and tumor profiling, along with data analytics platforms and development services for clinical and biopharmaceutical customers. The company does not currently have an established distribution program. This security may appeal to investors seeking exposure to oncology diagnostics and cancer research innovation rather than current income.

GH performance versus SPY

Price and return data through 2026-10-16.

Total return is 392.5% over the past 8 years, 195.3 points ahead of SPY at 197.2%. Over the past year its total return — price change plus distributions reinvested — is 135.1%. Its deepest 1-year drawdown was 33.0%.

GH key facts

Asset type

Stock

Asset class

Equity

Inception date

10/04/2018

Distribution frequency

None

Last close

$158.60 (as of 2026-10-16)

Market cap

$21,283,512,562

Average volume

1975309.0

Beta

1.583

Payout ratio

0.0%

EPS

$-3.52

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GH risks and drawbacks

The deepest 1-year drawdown on record here is 33.0%.

Who may consider GH — and who may not

It is a weaker fit for investors who need monthly cash flow (GH does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on GH

• ETFs holding GH
• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions